# ABLE: Abilify in Bipolar Disorder for Long-term Effectiveness

> **NCT00484471** · PHASE4 · COMPLETED · sponsor: **Korea Otsuka International Asia Arab** · enrollment: 127 (actual)

## Conditions studied

- Bipolar Disorder

## Interventions

- **DRUG:** aripiprazole
- **DRUG:** valproate
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00484471
- **Lead sponsor:** Korea Otsuka International Asia Arab
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2011-11
- **Final completion:** 2012-11
- **Target enrollment:** 127 (ACTUAL)
- **Last updated:** 2022-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00484471

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00484471, "ABLE: Abilify in Bipolar Disorder for Long-term Effectiveness". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00484471. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*